Author:
Demetri George D.,Benjamin Robert S.,Blanke Charles D.,Blay Jean-Yves,Casali Paolo,Choi Haesun,Corless Christopher L.,Debiec-Rychter Maria,DeMatteo Ronald P.,Ettinger David S.,Fisher George A.,Fletcher Christopher D. M.,Gronchi Alessandro,Hohenberger Peter,Hughes Miranda,Joensuu Heikki,Judson Ian,Le Cesne Axel,Maki Robert G.,Morse Michael,Pappo Alberto S.,Pisters Peter W. T.,Raut Chandrajit P.,Reichardt Peter,Tyler Douglas S.,Van den Abbeele Annick D.,von Mehren Margaret,Wayne Jeffrey D.,Zalcberg John
Abstract
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST. (JNCCN 2007;5[Suppl 2]:S1–S29)